JW THERAP-B (02126) announced that on May 19, 2026, the company, in accordance with the terms of the post-IPO incentive plan adopted on October 14, 2020, granted a total of 2 million share options to Mr. Tian Feng, the company's Executive Director and Chief Executive Officer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.